Differences in the prevention and control of cardiovascular and cerebrovascular diseases
C Liu, L Du, S Wang, L Kong, S Zhang, S Li… - Pharmacological …, 2021 - Elsevier
At present, the prevention and control of cardiovascular diseases (CAVDs) has made initial
advancements, although the prevention and control of cerebrovascular diseases (CEVDs) …
advancements, although the prevention and control of cerebrovascular diseases (CEVDs) …
[HTML][HTML] Mechanism of improving aspirin resistance: blood-activating herbs combined with aspirin in treating atherosclerotic cardiovascular diseases
Y Zhao, S Yang, M Wu - Frontiers in Pharmacology, 2021 - frontiersin.org
Atherosclerotic thrombotic disease continues to maintain a high morbidity and mortality rate
worldwide at present. Aspirin, which is reckoned as the cornerstone of primary and …
worldwide at present. Aspirin, which is reckoned as the cornerstone of primary and …
Antithrombotic strategy in secondary prevention for high-risk patients with previous acute coronary syndrome: overlap between the PEGASUS eligibility and the …
M Millesimo, E Elia, G Marengo, O De Filippo… - American Journal of …, 2023 - Springer
Background Patients with previous acute coronary syndrome (ACS) are at high risk of
recurrent adverse cardiovascular events. Recently, prolonged dual antiplatelet therapy …
recurrent adverse cardiovascular events. Recently, prolonged dual antiplatelet therapy …
Chinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 edition)
Y Zhang, J Yang, G Chang, H Cong, Q Dong… - Cardiology …, 2024 - ingentaconnect.com
Pan-vascular disease is a systemic condition characterized by vascular lesions, with
atherosclerosis comprising 95% of cases, manifesting as coronary artery disease …
atherosclerosis comprising 95% of cases, manifesting as coronary artery disease …
Estimated aggregate treatment benefit with addition of multiple novel medications for secondary prevention of atherosclerotic cardiovascular disease
Purpose: Interest in improving residual cardiovascular (CV) risk by targeting multiple
causative pathways has been growing. Several medications including icosapent ethyl …
causative pathways has been growing. Several medications including icosapent ethyl …
Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network …
S Verma, SG Goodman, MK Tan… - … Journal of Clinical …, 2021 - Wiley Online Library
Background Although acetylsalicylic acid is the most commonly used antithrombotic agent
for the secondary prevention of cardiovascular events, residual atherothrombotic risk has …
for the secondary prevention of cardiovascular events, residual atherothrombotic risk has …
[HTML][HTML] The impact of antithrombotic therapy on the time of detection of bladder cancer
D Jakus, M Šitum, P Čepin, I Vrhovac… - … European Journal of …, 2023 - ncbi.nlm.nih.gov
Results A lower frequency of high-grade bladder cancer (40.6% vs 60.1%, P= 0.006), T2
stage (7.2% vs 20.2%, P= 0.014), and a lower frequency of tumors larger than 3.5 cm (29 …
stage (7.2% vs 20.2%, P= 0.014), and a lower frequency of tumors larger than 3.5 cm (29 …
[PDF][PDF] Reducing Thrombotic Risk From Polyvascular Disease in Primary Care.
S Brunton - Journal of Family Practice, 2022 - pceconsortium.org
INTRODUCTION Polyvascular disease is defined as the presence of atherosclerosis in 2 or
more arterial beds, and is most commonly described as a combination of coronary artery …
more arterial beds, and is most commonly described as a combination of coronary artery …
Pathological Mineralisation
E Tsolaki - 2020 - discovery.ucl.ac.uk
Pathological mineralisation is a well-known phenomenon in the medical field as it relates to
a wide range of diseases, including cancer, neurodegenerative dis-eases, aortic valve …
a wide range of diseases, including cancer, neurodegenerative dis-eases, aortic valve …